[company_age]16.0[/company_age][employees]11-50 employees[/employees][funding]Series C[/funding][description]CYTOO is a preclinical stage drug discovery company specializing in muscular and neuromuscular disorders. They partner their versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develop their own drug candidates. CYTOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Their core expertise lies in in vitro muscle regeneration, contraction, hypertrophy, and metabolism. This expertise sets them apart from competitors by allowing them to develop more effective and targeted therapies for muscular and neuromuscular disorders.[/description][ps]CYTOO offers a versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates. They also offer a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic).[/ps]